Cite

HARVARD Citation

    Lee, V. et al. (n.d.). A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). European journal of cancer. pp. S12-. [Online]. 
  
Back to record